DXC025

DXC025 is a novel bispecific antibody-drug conjugate (ADC) designed to target both Mucin 1 (MUC1) and Epidermal Growth Factor Receptor (EGFR). Developed by Hangzhou DAC Biotechnology, the agent utilizes a bispecific Fab/scFv antibody architecture generated through knob-into-hole technology. This bispecific antibody is conjugated to tubulysin B analog payloads via a functional peptidyl spacer/linker. DXC025 is engineered to treat solid tumors where MUC1 and EGFR are co-expressed, such as colon, pancreatic, and non-small cell lung cancers. By targeting two tumor-associated antigens, the drug aims to enhance tumor selectivity, increase internalization efficiency, and reduce on-target/off-tumor toxicity compared to monospecific ADCs. Preclinical studies presented at AACR 2024 demonstrated that DXC025 candidates exhibit potent in vitro cytotoxicity and superior in vivo tumor growth inhibition in cell-derived xenograft models of gastrointestinal and epidermal cancers.